

# Ginger J Gardner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9074737/publications.pdf>

Version: 2024-02-01

69  
papers

2,220  
citations

279487

23  
h-index

233125

45  
g-index

71  
all docs

71  
docs citations

71  
times ranked

2634  
citing authors

#	ARTICLE	IF	CITATIONS
1	Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document. <i>Gynecologic Oncology</i> , 2011, 122, 190-198.	0.6	254
2	Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies. <i>Gynecologic Oncology</i> , 2014, 133, 274-277.	0.6	246
3	A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer. <i>Gynecologic Oncology</i> , 2014, 134, 455-461.	0.6	180
4	Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 140, 436-442.	0.6	97
5	The feasibility and safety of same-day discharge after robotic-assisted hysterectomy alone or with other procedures for benign and malignant indications. <i>Gynecologic Oncology</i> , 2014, 133, 552-555.	0.6	75
6	Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2015, 138, 246-251.	0.6	71
7	Impact of Obesity on Sentinel Lymph Node Mapping in Patients with Newly Diagnosed Uterine Cancer Undergoing Robotic Surgery. <i>Annals of Surgical Oncology</i> , 2016, 23, 2522-2528.	0.7	69
8	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2594-2604.	0.8	66
9	Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?. <i>Gynecologic Oncology</i> , 2018, 151, 24-31.	0.6	64
10	Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy. <i>Gynecologic Oncology</i> , 2020, 156, 147-153.	0.6	61
11	A pilot study of topical imiquimod therapy for the treatment of recurrent extramammary Paget's disease. <i>Gynecologic Oncology</i> , 2016, 142, 139-143.	0.6	57
12	Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?. <i>Gynecologic Oncology</i> , 2017, 145, 15-20.	0.6	55
13	Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes. <i>Gynecologic Oncology</i> , 2020, 156, 591-597.	0.6	54
14	Is It Time to Centralize Ovarian Cancer Care in the United States?. <i>Annals of Surgical Oncology</i> , 2016, 23, 989-993.	0.7	44
15	Impact of Robotic Platforms on Surgical Approach and Costs in the Management of Morbidly Obese Patients with Newly Diagnosed Uterine Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 2192-2198.	0.7	43
16	A comparative analysis of prediction models for complete gross resection in secondary cytoreductive surgery for ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 145, 230-235.	0.6	43
17	Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2017, 147, 262-266.	0.6	43
18	Diverting ileostomy during primary debulking surgery for ovarian cancer: Associated factors and postoperative outcomes. <i>Gynecologic Oncology</i> , 2016, 142, 217-224.	0.6	42

#	ARTICLE	IF	CITATIONS
19	Fellowship learning curve associated with completing a robotic assisted total laparoscopic hysterectomy. <i>Gynecologic Oncology</i> , 2014, 132, 102-106.	0.6	40
20	Development of a risk stratification system to guide treatment for female germ cell tumors. <i>Gynecologic Oncology</i> , 2015, 138, 566-572.	0.6	34
21	Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes. <i>Gynecologic Oncology</i> , 2017, 146, 263-267.	0.6	33
22	Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival. <i>Gynecologic Oncology</i> , 2018, 150, 44-49.	0.6	30
23	Pre-operative neoadjuvant chemotherapy cycles and survival in newly diagnosed ovarian cancer: what is the optimal number? A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1915-1921.	1.2	29
24	Evolution and outcomes of sentinel lymph node mapping in vulvar cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 383-386.	1.2	25
25	Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center. <i>Gynecologic Oncology</i> , 2019, 154, 77-82.	0.6	24
26	Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status. <i>Gynecologic Oncology</i> , 2019, 154, 144-149.	0.6	24
27	A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative. <i>Gynecologic Oncology</i> , 2020, 158, 608-613.	0.6	23
28	A single-arm, prospective trial investigating the effectiveness of a non-hormonal vaginal moisturizer containing hyaluronic acid in postmenopausal cancer survivors. <i>Supportive Care in Cancer</i> , 2021, 29, 311-322.	1.0	22
29	Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e17.	1.0	22
30	Risk factors for financial toxicity in patients with gynecologic cancer. <i>American Journal of Obstetrics and Gynecology</i> , 2022, 226, 817.e1-817.e9.	0.7	20
31	Is Robotic-Assisted Surgery Safe in the Elderly Population? An Analysis of Gynecologic Procedures in Patients ≥65 Years Old. <i>Annals of Surgical Oncology</i> , 2019, 26, 244-251.	0.7	18
32	Risk of venous thromboembolism in ovarian cancer patients receiving neoadjuvant chemotherapy. <i>Gynecologic Oncology</i> , 2021, 163, 36-40.	0.6	18
33	Current and Future Directions of Clinical Trials for Ovarian Cancer. <i>Cancer Control</i> , 2011, 18, 44-51.	0.7	17
34	Abdominal wall endometriosis: differentiation from other masses using CT features. <i>Abdominal Radiology</i> , 2017, 42, 1517-1523.	1.0	16
35	A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2018, 151, 433-437.	0.6	16
36	Role of delayed interval debulking for persistent residual disease after more than 5 cycles of chemotherapy for primary advanced ovarian cancer. An international multicenter study. <i>Gynecologic Oncology</i> , 2020, 159, 434-441.	0.6	16

#	ARTICLE	IF	CITATIONS
37	Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes. <i>Annals of Surgical Oncology</i> , 2020, 27, 3772-3780.	0.7	16
38	A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors. <i>Gynecologic Oncology</i> , 2020, 158, 366-374.	0.6	15
39	Robotically Assisted Laparoscopic Ovarian Transposition in Women with Lower Gastrointestinal Cancer Undergoing Pelvic Radiotherapy. <i>Annals of Surgical Oncology</i> , 2017, 24, 251-256.	0.7	14
40	Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 161, 687-692.	0.6	14
41	Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center. <i>Gynecologic Oncology</i> , 2016, 143, 496-503.	0.6	12
42	Prospective Comparative Study of Laparoscopic Narrow Band Imaging (NBI) Versus Standard Imaging in Gynecologic Oncology. <i>Annals of Surgical Oncology</i> , 2018, 25, 984-990.	0.7	12
43	Video-assisted thoracic surgery in the primary management of advanced ovarian carcinoma with moderate to large pleural effusions: A Memorial Sloan Kettering Cancer Center Team Ovary Study. <i>Gynecologic Oncology</i> , 2020, 159, 66-71.	0.6	12
44	Parenchymal splenic metastasis is an independent negative predictor of overall survival in advanced ovarian, fallopian tube, and primary peritoneal cancer. <i>Gynecologic Oncology</i> , 2013, 128, 28-33.	0.6	11
45	Herniation formation in women undergoing robotically assisted laparoscopy or laparotomy for endometrial cancer. <i>Gynecologic Oncology</i> , 2016, 140, 383-386.	0.6	10
46	Ovarian cancer recurrence detection may not require in-person physical examination: an MSK team ovary study. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 159-164.	1.2	10
47	Ovarian Cancer Cytoreductive Surgery in the Elderly. <i>Current Treatment Options in Oncology</i> , 2009, 10, 171-179.	1.3	9
48	Tertiary cytoreduction for recurrent ovarian carcinoma: An updated and expanded analysis. <i>Gynecologic Oncology</i> , 2021, 162, 345-352.	0.6	8
49	Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer. <i>Scientific Reports</i> , 2022, 12, 974.	1.6	8
50	Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2017, 147, 371-374.	0.6	7
51	State of the science: Evolving role of surgery for the treatment of ovarian cancer. <i>Gynecologic Oncology</i> , 2019, 155, 3-7.	0.6	7
52	Understanding Inherited Risk in Unselected Newly Diagnosed Patients With Endometrial Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	7
53	The impact of near-infrared angiography and proctoscopy after rectosigmoid resection and anastomosis performed during surgeries for gynecologic malignancies. <i>Gynecologic Oncology</i> , 2020, 158, 397-401.	0.6	7
54	Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 418-425.	0.6	7

#	ARTICLE	IF	CITATIONS
55	Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1554-1561.	1.2	7
56	CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: A gynecologic oncology group study. <i>Gynecologic Oncology</i> , 2012, 124, 216-220.	0.6	6
57	Comparison of minimally invasive versus open surgery in the treatment of endometrial carcinosarcoma. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1162-1168.	1.2	6
58	Hematologic changes after splenectomy for ovarian cancer debulking surgery, and association with infection and venous thromboembolism. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1183-1188.	1.2	4
59	Surveillance patterns of cervical cancer patients treated with conization alone. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1129-1135.	1.2	3
60	Implementation of Evidence-Based Presurgical Testing Guidelines in Patients Undergoing Ambulatory Surgery for Endometrial Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e219-e224.	1.4	3
61	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center. <i>Gynecologic Oncology</i> , 2016, 142, 13-18.	0.6	2
62	Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study. <i>Gynecologic Oncology</i> , 2021, 160, 51-55.	0.6	2
63	Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study. <i>Gynecologic Oncology</i> , 2021, 160, 696-703.	0.6	2
64	Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers. <i>Gynecologic Oncology</i> , 2021, 161, 521-526.	0.6	2
65	Recurrent Ovarian Cancer “Sculpting a Promising Future with Surgery. <i>New England Journal of Medicine</i> , 2021, 385, 2187-2188.	13.9	2
66	Gynecologic Survivorship Tool: Development, Implementation, and Symptom Outcomes. <i>JCO Clinical Cancer Informatics</i> , 2022, 6, e2100154.	1.0	2
67	Quaternary and beyond cytoreduction: An updated and expanded analysis. <i>Gynecologic Oncology Reports</i> , 2021, 37, 100851.	0.3	1
68	Enhanced Patient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. <i>Annals of Surgical Oncology</i> , 2022, 29, 1789-1796.	0.7	1
69	ASO Visual Abstract: Enhanced Patient Clinical Streamlining (EPACS) “Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits. <i>Annals of Surgical Oncology</i> , 2022, 29, 1805-1806.	0.7	0